For decades, central nervous system (CNS) disorders have been defined primarily through observable symptoms rather than measurable biology. Conditions such as major depressive disorder, Alzheimer’s disease, and Parkinson’s disease were historically grouped into broad syndromic categories because the underlying mechanisms driving disease were poorly understood.

Despite decades of investment, the overwhelming majority of programs have failed in late-stage development. Yet recent approvals targeting amyloid biology have demonstrated that regulatory success is achievable when scientific execution is paired with disciplined development strategy.

CNS disorders are increasingly being understood through molecular signatures, circuit-level dysfunction, and digitally derived behavioral patterns. This shift is not incremental it redefines how therapies must be discovered, developed, and approved.

A substantial proportion of patients fail to achieve sustained remission. Treatment resistance remains common, and relapse frequently follows initial response. These patterns suggest a structural limitation: incremental adjustments to synaptic signaling are no longer sufficient to meaningfully shift long-term outcomes at scale.

Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved. Organizations that continue to anchor development programs in broad diagnostic labels and legacy endpoints face a growing risk of failure. Not because their science lacks merit, but because their development strategies are misaligned with biological reality.

Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression.

Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression.

Sponsors who continue to build programs around broad diagnostic categories and legacy endpoints will increasingly fail not because their science lacks merit, but because their development strategy is misaligned with biological reality. Salience Clinical operates at the intersection of neuroscience, regulatory strategy, and precision development helping sponsors translate biological complexity into approvable labels, differentiated value, and durable market position.

For decades, psychiatry has approached major depressive disorder (MDD) as a disorder of neurochemistry—an imbalance of serotonin, norepinephrine, or dopamine. This framework has enabled meaningful progress. Yet it has not delivered durable remission at scale.

Advances in high-resolution functional MRI, multimodal imaging, and computational modeling over the past decade have significantly reshaped our understanding of depression. Rather than viewing major depressive disorder as a localized or purely neurochemical condition, it is now increasingly recognized as a disorder of distributed brain network dynamics. Converging evidence points to consistent dysregulation across three large-scale neural systems—collectively known as the “triple network”: the Salience Network (SN), the Central Executive (or Frontoparietal) Network (CEN/FPN), and the Default Mode Network (DMN).

Alzheimer’s disease (AD) drug development remains the highest-stakes arena in biopharma. While the "Alzheimer’s Graveyard" is littered with multi-billion dollar failures, a new era of amyloid and tau-targeting therapies has proven that the regulatory path is navigable but only for those with a disciplined risk architecture. Success in 2026 is driven by Translational Clarity: the ability to prove that biological changes translate into human functional benefit.

CNS disorders are now being reclassified by molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological upgrade; it is a strategic reset. Sponsors who continue to build programs around blunt diagnostic categories and legacy endpoints will increasingly fail, not because their science is weak, but because their development logic is obsolete.

Traditional pharmacotherapy primarily alters synaptic transmission. Neuromodulation platforms (such as rTMS, ECT, and invasive stimulation) primarily alter excitability in specific cortical or subcortical targets. But most existing approaches were not originally designed to deliberately recalibrate the balance and interaction of large-scale networks such as DMN, CEN/FPN, and SN.

Converging evidence also points to impaired SN-mediated switching between the DMN and executive networks, contributing to persistent self-focus and insufficient recruitment of cognitive control. Together, these findings support a systems-level imbalance an architectural problem in network coordination rather than a purely local neurotransmitter deficit.

At Salience Clinical, we operate at the intersection of systems neuroscience, clinical development strategy, biomarker integration, and translational positioning. Our focus is not theoretical neuroscience; it is applied architecture. We help teams translate emerging network science into concrete decisions about development pipelines, endpoint strategy, and evidence generation.

AAV-mediated delivery of enzymes, neurotransmitter-modulating proteins, or neurotrophic factors has been extensively explored in Parkinson’s disease. While early studies suggested biological activity, several randomized controlled trials failed to meet primary clinical endpoints, highlighting the challenges of placebo effects, target engagement, and disease heterogeneity.

CNS disorders are now being reclassified by molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological upgrade; it is a strategic reset. Sponsors who continue to build programs around blunt diagnostic categories and legacy endpoints will increasingly fail, not because their science is weak, but because their development logic is obsolete.

Healthcare systems face a growing economic crisis: more than 13 million patients suffer from chronic wounds each year, yet traditional health-economic models capture only a fraction of the true burden. Current accounting focuses on product prices and episode-level costs while missing the far larger impacts of delayed healing, lost productivity, caregiver strain, and preventable complications.

Real-world evidence (RWE) has emerged as an essential complement to clinical trials, offering continuous insights into implant durability, safety, effectiveness, and economic value across actual care settings. This white paper reviews the importance of RWE in orthopedics, key data sources including national registries and the Orthopedic Coordinated Registry Network (Ortho-CRN), regulatory context, advanced analytical methods, and future directions involving AI and federated data networks. Strategic guidance is provided for manufacturers aiming to integrate RWE into product development, regulatory compliance, market access, and innovation.

In an era where regulatory expectations, technological complexity, and global harmonization are accelerating, cross-functional excellence determines whether a device reaches patients on time—and with the safety and performance they deserve. Organizations that treat plans as living documents, invest early in collaborative risk management, and unify engineering, clinical, regulatory, and quality perspectives transform development complexity into meaningful patient impact.

Healthcare systems face a growing economic crisis: more than 13 million patients suffer from chronic wounds each year, yet traditional health-economic models capture only a fraction of the true burden. Current accounting focuses on product prices and episode-level costs while missing the far larger impacts of delayed healing, lost productivity, caregiver strain, and preventable complications.

Real-world evidence (RWE) has emerged as an essential complement to clinical trials, offering continuous insights into implant durability, safety, effectiveness, and economic value across actual care settings. This white paper reviews the importance of RWE in orthopedics, key data sources including national registries and the Orthopedic Coordinated Registry Network (Ortho-CRN), regulatory context, advanced analytical methods, and future directions involving AI and federated data networks. Strategic guidance is provided for manufacturers aiming to integrate RWE into product development, regulatory compliance, market access, and innovation.

Orthopedic implants are long-term, often lifelong, interventions that require rigorous evidence demonstrating sustained safety and performance. Traditional RCTs with limited follow-up and narrow populations cannot fully capture the complex real-world environment, especially given the variability in surgical techniques, patient comorbidities, and health system factors. As payer and regulatory expectations evolve, RWE has become indispensable for demonstrating lifetime device value and supporting continuous improvement.

Musculoskeletal regenerative medicine is approaching a commercial inflection point. What was once a speculative frontier cell therapies, bioengineered scaffolds, gene-modified constructs is now advancing first-generation clinical programs.